Antibody responses to the RTS,S/AS01_E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique.

ABSTRACT: The RTS,S/AS01_E vaccine has shown consistent but partial vaccine efficacy in a pediatric phase 3 clinical trial using a 3-dose immunization schedule. A fourth-dose 18 months after the primary vaccination was shown to restore the waning efficacy. However, only total IgG against the immunodominant malaria vaccine epitope has been analyzed following the booster. To better characterize the magnitude, nature, and longevity of the immune response to the booster, we measured levels of total IgM, IgG, and IgG_1-4 subclasses against three constructs of the circumsporozoite protein (CSP) and the hepatitis B surface antigen (HBsAg, also present in RTS,S) by quantitative suspension array technology in 50 subjects in the phase 3 trial in Manhiça, Mozambique. To explore the impact o

SUBMITTER: Sanchez L 

PROVIDER: S-EPMC7272643 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature